Ireland
--:--IST
Recruiting Phase 4

A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing Robotic-Assisted Bronchoscopy

NCT07761351 · tracked via the Priya Life Science UK tracker
Phase
Phase 4
Started
2026-08-28
Last updated
2026-09-25

Condition(s) studied

Lung Cancer (Diagnosis)Lung Nodule

Investigational drug(s) / intervention(s)

Shape-Sensing Robotic-Assisted Bronchoscopy with Cone-Beam CT (ssRAB with CBCT)CT-guided percutaneous lung nodule biopsy

Shape-Sensing Robotic-Assisted Bronchoscopy with Cone-Beam CT (ssRAB with CBCT): A bronchoscopic lung nodule biopsy procedure performed using shape-sensing robotic-assisted bronchoscopy with cone-beam CT guidance as clinically indicated and according to standard clinical practice.

CT-guided percutaneous lung nodule biopsy: A percutaneous lung nodule biopsy procedure performed under CT imaging guidance according to standard clinical practice.

Study summary

The ENCOMPASS study is a post-market, multicenter, randomized controlled trial comparing two established approaches for obtaining a biopsy of small pulmonary nodules (≤2 cm): CT-guided percutaneous lung nodule biopsy and shape-sensing robotic-assisted bronchoscopy with cone-beam CT (ssRAB with CBCT).

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patient is aged 18 years or older at time of consent. 2. Diagnostic nodule biopsy(s) indicated per multidisciplinary team (or equivalent). 3. Target pulmonary nodule ≤2 cm in largest diameter. 4. Patient is willing and able to give written informed consent for clinical study participation. Exclusion Criteria: 1. Patient has previously undergone a biopsy procedure of the target nodule by any approach. 2. Patient was previously randomized in this study but did not undergo biopsy. 3. Patient is participating in an interventional research study or research study with investigational agents with an unknown safety profile that would interfere with participation in this study or study results. 4. Patient is pregnant or breastfeeding as determined by standard site practices. 5. Patient lacks the capacity to provide informed consent for themselves, or is a vulnerable patient whose ability to protect their own interests or to consent freely may be diminished, including but not limited to, patients who may be unduly influenced through dependency on the sponsor, the hospital, or the study doctor. 6. Patient is not willing to comply with study participation requirements.

Primary outcome measure(s)

  • Diagnostic Efficacy of the Assigned Biopsy Procedure — At the index procedure
    Diagnostic efficacy will be calculated as the proportion of patients who receive their assigned treatment multiplied by diagnostic yield of their assigned treatment.
  • Peri-Procedural Pneumothorax Rate — From procedure to 7 days (or until subsequent intervention, whichever occurs first).
    Rate of peri-procedural pneumothorax related to the assigned index biopsy procedure, including pneumothorax identified on routine post-procedure imaging and clinically relevant pneumothorax requiring intervention or escalation of care.

Trial sites (3)

FacilityCityRegionStatus
Thoraxklinik Heidelberg Heidelberg Germany Recruiting
Basel University Hospital Basel Canton of Basel-City Recruiting
University College London Hospitals NHS Foundation London United Kingdom Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07761351 on ClinicalTrials.gov ↗ ← All trials in the UK